Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.

× No keyword cloud information.

31 in total

1. What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Authors: Tianjing Li; S Swaroop Vedula; Roberta Scherer; Kay Dickersin
Journal: Ann Intern Med Date: 2012-03-06 Impact factor: 25.391

2. Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

Authors: Robert N Weinreb; Paul L Kaufman
Journal: Invest Ophthalmol Vis Sci Date: 2011-10-04 Impact factor: 4.799

3. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.

Authors: Rohit Varma; Elaine A Richman; Frederick L Ferris; Neil M Bressler
Journal: Invest Ophthalmol Vis Sci Date: 2010-12 Impact factor: 4.799

4. Evaluation of Visual Field and Imaging Outcomes for Glaucoma Clinical Trials (An American Ophthalomological Society Thesis).

Authors: David F Garway-Heath; Ana Quartilho; Philip Prah; David P Crabb; Qian Cheng; Haogang Zhu
Journal: Trans Am Ophthalmol Soc Date: 2017-08-22

5. Test-retest repeatability of the pattern electroretinogram and flicker electroretinogram.

Authors: Arthur F Resende; Carina T Sanvicente; Hamoon Eshraghi; Alberto Garcia; Kassandra Pickel; Qiang Zhang; Michael Waisbourd; L Jay Katz
Journal: Doc Ophthalmol Date: 2019-07-16 Impact factor: 2.379

6. [Transorbital alternating current in optic neuropathy : December 2016. Opinion of the DOG and BVA on "Gall C et al. Alternating current stimulation for vision restoration after optic nerve damage: a randomized clinical trial. PLoS One 2016"].

Authors:
Journal: Ophthalmologe Date: 2017-02 Impact factor: 1.059

The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.

1. What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

2. Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

3. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.

4. Evaluation of Visual Field and Imaging Outcomes for Glaucoma Clinical Trials (An American Ophthalomological Society Thesis).

5. Test-retest repeatability of the pattern electroretinogram and flicker electroretinogram.

6. [Transorbital alternating current in optic neuropathy : December 2016. Opinion of the DOG and BVA on "Gall C et al. Alternating current stimulation for vision restoration after optic nerve damage: a randomized clinical trial. PLoS One 2016"].

7. Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.

Review 8. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.

9. The Frequency of Optical Coherence Tomography Testing in Glaucoma at a Single Academic Medical Center.

Review 10. Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.